Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
3.370
+0.010 (0.30%)
At close: Mar 11, 2026, 4:00 PM EDT
3.360
-0.010 (-0.30%)
After-hours: Mar 11, 2026, 5:48 PM EDT
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
204.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 1.44M | -261.00K | -15.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 149.50M |
| Arcturus Therapeutics Holdings | 82.03M |
| Compugen | 72.76M |
| Zentalis Pharmaceuticals | 26.87M |
| ProQR Therapeutics | 18.86M |
| Whitehawk Therapeutics | 14.38M |
| Caribou Biosciences | 11.16M |
| SAB Biotherapeutics | 114.70K |
ABOS News
- 1 day ago - Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - GlobeNewsWire
- 4 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 7 months ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 7 months ago - Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 8 months ago - JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire